EGFR and urinary bladder carcinoma: In addition to targeting EGFR, another CUR analogue, BDMC, was reported to promote the suppressive effect of PDL-1 antibody on bladder cancer progression via stimulating cytotoxic T-cell activity and suppressing myeloid-derived suppressor cells (MDSCs) in an immunocompetent mice model [59], suggesting that DMC might be also an immunomodulatory compound in the tumor microenvironment.